Tuesday 26 October, 2021 – Biotherapeutics characterization

Innovative antibody therapeutics and SPR
Chifumi Teramoto (Seida)
Chugai Pharmaceutical Co., Ltd. Discovery Biologics Dept. Protein Analysis Group, Research Div., Japan

A surface plasmon resonance based approach for measuring response to pneumococcal vaccine
Dr. Leonor Puchades Carrasco, Drug Dicovery Unit, Health Research Institute La Fe, Valencia, Spain

Biacore™ systems for viral vector titer analysis
Anna Moberg, Senior Scientist, Cytiva, Uppsala, Sweden

Half-life extension and formatting of high affinity Affimer molecules
Dr. Emma Jenkins, PhD, Avacta Life Sciences Ltd., Cambridge, United Kingdom

Too much, too low: Structure Activity Relationship study of mAb a-fucosylated and high-mannose variants
Dr. Giordana Bruni Merck Serono S.p.A, Rome, Italy

Novel analytics to improve quality control and validation update
Fredrik Sundberg, Global Director,Strategic Technologies, Cytiva

Panel discussion
Moderators: Helena Blomquist and Paul Belcher and

Panelist: Anna Moberg, Vishal Kamat


Post your image for “Sensorgramseverywhere gallery” ― vote for your favorite


Wednesday 27 October, 2021 – Fragment/LMW compound screening and characterization

Applications of SPR for small molecule drug discovery in oncology projects at AstraZeneca
Dr. Philip Rawlins, AstraZeneca, Cambridge, United Kingdom

Characterizing PROTAC ternary structures using SPR
Dr. David Zollman, The University of Dundee, Dundee, United Kingdom

Direct or capture based coupling? Place your bets
Dr. Emeric Gueneau, Cytiva, Vélizy-Villacoublay, France

Development of orally efficacious allosteric inhibitors of TNFα via fragment-based drug design
Dr.Sanjay C. Panchal, Ph.D., Abbvie, North Chicago, IL, USA

Small but Mighty (Part 1) – SPR assay design for generation of high-quality data for drug compound (LMW) assays
Dr. Cynthia, Shuman, Cytiva, USA

Measuring extreme kinetics using label-free SPR
John G. Quinn, Genentech Inc., San Francisco, CA, United States of America

Panel discussion
Moderators: Helena Blomquist and Paul Belcher

Guests: Dr Sanjay C. Panchal and Dr. Cynthia Shuman

Thursday 28 October, 2021 – What does SPR data tell you

SPR-assisted antibody selection for IVD SARS-CoV2 assay development
Ute Jucknischke, Roche Diagnostics GmbH, Diagnostic Solutions,
Antibody Development Technologies, Penzberg, Germany

Learn one and manage multiple Biacore™ systems.
Dr. John Sinfield, Cytiva, Cambridge, United Kingdom

Small but Mighty Part 2: Data analysis and trouble-shooting LMW and Fragment Biacore SPR data – decisions, decisions.
Michael Murphy, Cytiva, xxx, United States of America

Navigating the wonderland of drug discovery: Finding the (critical) path for efficient evaluation of data
Paul Belcher, Cytiva, Boston, MA United States of America

Leveraging supervised machine learning in SPR data analysis
Dr. Katie Del Vecchio, Relay Therapeutics, Cambridge, MA, United States of America

Biacore™ software in the Cloud – now sensorgrams are everywhere!
Dr. John Sinfield, Cytiva, Cambridge, United Kingdom

Panel discussion
Moderators: Helena Blomquist and Paul Belcher

Guest: Dr. Katie Del Vecchio, Relay Therapeutics